Two years after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in
December 2019, the first infections were identified in Wuhan city of China. SARS-CoV-2 …

The rapid development and deployment of mRNA and adenovirus-vectored vaccines
against coronavirus disease 2019 (COVID-19) continue to astound the global scientific …

The production of subunit nanovaccines relies heavily on the development of a vaccine
delivery system that is safe and efficient at delivering antigens to the target site …

The development of recombinant COVID-19 vaccines has resulted from scientific progress
made at an unprecedented speed during 2020. The recombinant spike glycoprotein …

Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD
conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity …

Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r-receptor binding domain (RBD) protein vaccines. Methods A …

Immunization has the potential to become a viable weapon for the upcoming pandemic and
save millions of lives, while also dramatically lowering the high mortality rate brought on by a …

COVID-19 has been spreading worldwide since late 2019. There is no definitive cure to
date. Global vaccination programs are urgently required to confer herd immunity, reducing …

Multivalent display of SARS-CoV-2 RBDs (receptor-binding domains, prime proteins for viral
infection and as vaccine immunogens) affects infectivity and as immunogens on a virus-like …